Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alitretinoin Retreatment and Extension in Chronic Hand Dermatitis
NCT00124436Phase 3Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Mar 2005
- Primary completion
- Jan 2007
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alitretinoin in chronic hand dermatitis (CHE) (4 arms), sponsored by Basilea Pharmaceutica. Primary endpoint: Physician's Global Assessment at 24 weeks. Started Mar 2005; status: completed.
02
Drugs
alitretinoin
03
Conditions
chronic hand dermatitis (CHE)
Beyond the preview
Go deeper on NCT00124436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124436.